These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34986169)

  • 1. Transmission and containment of the SARS-CoV-2 Delta variant of concern in Guangzhou, China: A population-based study.
    Li L; Han ZG; Qin PZ; Liu WH; Yang Z; Chen ZQ; Li K; Xie CJ; Ma Y; Wang H; Huang Y; Fan SJ; Yan ZL; Ou CQ; Luo L
    PLoS Negl Trop Dis; 2022 Jan; 16(1):e0010048. PubMed ID: 34986169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.
    Jing QL; Liu MJ; Zhang ZB; Fang LQ; Yuan J; Zhang AR; Dean NE; Luo L; Ma MM; Longini I; Kenah E; Lu Y; Ma Y; Jalali N; Yang ZC; Yang Y
    Lancet Infect Dis; 2020 Oct; 20(10):1141-1150. PubMed ID: 32562601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transmission dynamics and successful control measures of SARS-CoV-2 in the mega-size city of Guangzhou, China.
    Zhao H; Zhang Z; Lun W; Chen Z; Lu X; Li J; Qiu F; Li S; Mao C; Lu Y; Chen J; He Q; Lu J; Yang Z
    Medicine (Baltimore); 2021 Dec; 100(48):e27846. PubMed ID: 35049185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
    Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
    Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epidemiological characteristics of local outbreak of COVID-19 caused by SARS-CoV-2 Delta variant in Liwan district, Guangzhou].
    Li WY; Du ZC; Wang Y; Lin X; Lu L; Fang Q; Zhang WF; Cai MW; Xu L; Hao YT
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1763-1768. PubMed ID: 34814609
    [No Abstract]   [Full Text] [Related]  

  • 6. Transmission characteristics and inactivated vaccine effectiveness against transmission of the SARS-CoV-2 Omicron BA.2 variant in Shenzhen, China.
    He X; Liao Y; Liang Y; Yu J; Gao W; Wan J; Liao Y; Su J; Zou X; Tang S
    Front Immunol; 2023; 14():1290279. PubMed ID: 38259438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
    Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
    Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 Infections and Hospitalizations Among Persons Aged ≥16 Years, by Vaccination Status - Los Angeles County, California, May 1-July 25, 2021.
    Griffin JB; Haddix M; Danza P; Fisher R; Koo TH; Traub E; Gounder P; Jarashow C; Balter S
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1170-1176. PubMed ID: 34437525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmission Characteristics and Inactivated Vaccine Effectiveness Against Transmission of SARS-CoV-2 Omicron BA.5 Variants in Urumqi, China.
    Wang K; Guo Z; Zeng T; Sun S; Lu Y; Wang J; Li S; Luan Z; Li H; Zhang J; Wang Y; Lu Y; Zhao S
    JAMA Netw Open; 2023 Mar; 6(3):e235755. PubMed ID: 36995713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
    Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
    Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmission dynamics and control of two epidemic waves of SARS-CoV-2 in South Korea.
    Ryu S; Ali ST; Noh E; Kim D; Lau EHY; Cowling BJ
    BMC Infect Dis; 2021 May; 21(1):485. PubMed ID: 34039296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 Delta Variant Breakthrough Infection and Onward Secondary Transmission in Household.
    Yi S; Kim JM; Choe YJ; Hong S; Choi S; Ahn SB; Kim M; Park YJ
    J Korean Med Sci; 2022 Jan; 37(1):e12. PubMed ID: 34981682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
    Zhang Y; Belayachi J; Yang Y; Fu Q; Rodewald L; Li H; Yan B; Wang Y; Shen Y; Yang Q; Mu W; Tang R; Su C; Xu T; Obtel M; Mhayi A; Razine R; Abouqal R; Zhang Y; Yang X
    BMC Public Health; 2022 Aug; 22(1):1584. PubMed ID: 35987605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of "Hierarchical and Classified Prevention and Control Measures (HCPC)" Strategy for SARS-CoV-2 Delta Variant in Guangzhou: A Modeling Study.
    Ma Y; Wang H; Huang Y; Chen C; Liang S; Ma M; He X; Cai K; Jiao Z; Chen L; Zhu B; Li K; Xie C; Luo L; Zhang Z
    J Epidemiol Glob Health; 2023 Jun; 13(2):303-312. PubMed ID: 37258853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CoronaVac and BBIBP-CorV vaccines against SARS-CoV-2 during predominant circulation of Omicron BA.5.2 and BF.7 in China, a retrospective cohort study.
    Hu Z; Jin Z; Zhou M; Zhang C; Bao Y; Gao X; Wang G
    J Med Virol; 2023 Oct; 95(10):e29143. PubMed ID: 37814963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Sonabend R; Whittles LK; Imai N; Perez-Guzman PN; Knock ES; Rawson T; Gaythorpe KAM; Djaafara BA; Hinsley W; FitzJohn RG; Lees JA; Kanapram DT; Volz EM; Ghani AC; Ferguson NM; Baguelin M; Cori A
    Lancet; 2021 Nov; 398(10313):1825-1835. PubMed ID: 34717829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmission Dynamics of the Delta Variant of SARS-CoV-2 Infections in South Korea.
    Hwang H; Lim JS; Song SA; Achangwa C; Sim W; Kim G; Ryu S
    J Infect Dis; 2022 Mar; 225(5):793-799. PubMed ID: 34865022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epidemiological characteristics of two local COVID-19 outbreaks caused by 2019-nCoV Omicron variant in Guangzhou, China].
    Huang Y; Zheng ZW; Chen C; Li K; Chen SY; Chen YY; Jing QL; Ma Y; Luo L; Yang ZC; Zhang ZB
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Nov; 43(11):1705-1710. PubMed ID: 36444451
    [No Abstract]   [Full Text] [Related]  

  • 20. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.